Sort
40,608 grants matching “prostate cancer”
Human PSMA MAb Radioimmunotherapy for Prostate Cancer
$891,936Progenics Pharmaceuticals, Inc. · R44 · FY2004 · CA
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
$891,935Romonia Renee Reams · Florida Agricultural And Mechanical Univ · U54 · FY2021 · CA
ETCTN with Phase 2 Emphasis
$891,704Edward Chu · University Of Pittsburgh At Pittsburgh · UM1 · FY2016 · CA
The Molecular Profile of Prostate Tumors in African-American Men
$891,624Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Maryland Prostate Cancer Case-Control Study
$891,624Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
IDENTIFYING GENOMIC DRIVERS OF PROSTATE CANCER PROGRESSION AND DRUG RESISTANCE IN TUMORS AND CIRCULATING DNA
$891,279Sloan-Kettering Institute For Cancer Research · · FY2017 · Department of the Army
Analysis of Human Immune Reponses in Cancer Vaccine Clinical Trials
$891,242Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Development of PSMA -based recombinant protein vaccines
$891,229Gerald P Donovan · Progenics Pharmaceuticals, Inc. · R44 · FY2006 · CA
MEASURING PATIENT-REPORTED OUTCOMES RELATED TO RADIOPHARMACEUTICALS FOR PROSTATE CANCER
$890,992H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. · · FY2020 · Defense Health Agency
Cancer Immunotherapy Clinical Trials
$890,340Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Prostate Cancer Studies
$890,062Michael Cook · Division Of Cancer Epidemiology And Genetics · ZIA · FY2017 · CA
NEW AWARD - POLYPLOID GIANT CANCER CELLS ACTUATE PROSTATE CANCER TUMOR RESISTANCE AND LETHAL PHENOTYPE...EFFECTIVE DATE 15 JUN 2020, DATE SIGNED 27-MAY-2020, DISTRIBUTED JUNE 1, 2020, FAADC JUNE 1, 2020
$889,926The Johns Hopkins University · · FY2020 · Defense Health Agency
National Capital Area (NCA) Minority/Underserved NCORP
$889,690Lucile L Adams-Campbell · Georgetown University · UG1 · FY2022 · CA
National Capital Area (NCA) Minority/Underserved NCORP
$889,690Lucile L Adams-Campbell · Georgetown University · UG1 · FY2019 · CA
MOUSE CANCER MODELS VIA TGF-BETA RII LOSS
$888,503Vanderbilt University · U01 · FY2003 · CA
Enabling Next Generation Machine Learning for Large Scale Image Analysis
$888,411Gerald Sabin · Rnet Technologies, Inc. · R44 · FY2024 · EB
Using Clinical Pharmacology Principles to Develop New Anticancer Therapies
$887,976William Douglas Figg · Division Of Clinical Sciences - Nci · ZIC · FY2020 · CA
Identification of human tumor-associated antigens
$887,872Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Signal Transduction Events and the Regulation of Cell Growth
$887,075Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2012 · CA
THE ROLE OF METASTASIS-ASSOCIATED PROTEASES AND PEPTIDES IN PROSTATE CANCER
$886,950Ada Forsyth Institute, Inc. · · FY2013 · Department of the Army
INVESTIGATING THE EXPRESSION, ROLE, AND TARGETING OF COLLAGEN MODIFYING PROLYL 4-HYDROXYLASE P4HA1 IN PROSTATE CANCER PROGRESSION AND METASTASIS
$886,809University Of Alabama At Birmingham · · FY2019 · Defense Health Agency
AGING AND MALE REPRODUCTIVE TRACT STRUCTURE/FUNCTION
$886,551Johns Hopkins University · P01 · FY2001 · AG
Epigenetics, Stem Cells, and Cancer
$886,353Rudolf Jaenisch · Whitehead Institute For Biomedical Res · R01 · FY2009 · CA
An Improved Epigenetic Algorithm for Guiding Low Dose CT Lung Cancer Screening
$885,606Robert A Philibert · Bd Holding, Inc. · R44 · FY2023 · CA
TR&D1: Development of Improved DNP Methodology and HP MR Acquisition Techniques
$885,131Daniel B Vigneron · University Of California, San Francisco · P41 · FY2016 · EB